

#60

COMPLETE

**Collector:** Email Invitation 1 (Email)  
**Started:** Wednesday, April 25, 2018 10:39:15 AM  
**Last Modified:** Wednesday, April 25, 2018 10:53:21 AM  
**Time Spent:** 00:14:05  
**First Name:** [REDACTED]  
[REDACTED]  
[REDACTED]  
[REDACTED]

Page 2: General Information

Q1 Focal point contact details

Name [REDACTED]  
[REDACTED] onal  
[REDACTED]; [REDACTED]  
[REDACTED]  
[REDACTED] e

Q2 Please indicate your country Germany

Page 3: WHO Data Sharing Policy

Q3 Please confirm that you agree I agree for the information provided in this questionnaire to be published in a report

Page 4: General cannabis information

Q4 Do you have any information about the use of THC for any purpose (including medical or non-medical use) in your country? Yes

Page 5: Medical use

Q5 At national level, is THC legally approved for medical use in your country? Yes

Page 6: Medical use: Therapeutic indications

WHO ECDD Questionnaire: delta-9-tetrahydrocannabinol (THC)

**Q6** Please indicate any approved therapeutic indications for the use of THC in your country

Other (please specify):

Concerning pharmacy-prepared medicinal products containing THC there are no limitations to specific therapeutic indications but there's the limitation that only severely ill patients can receive medicinal cannabis who according to a doctor's decision can't be treated properly with other medications.

**Q7** Please indicate any symptoms that THC is approved to treat

**Nausea/ vomiting,**

Other (please specify):

Concerning pharmacy-prepared medicinal products containing THC there are no limitations to specific symptoms but there's the limitation that only severely ill patients can receive medicinal cannabis who according to a doctor's decision can't be treated properly with other medications.

**Q8** Please indicate whether there are any permitted marketed products of THC.

Name of marketed product & CBD /THC content (if known):

**Canemes (capsules with 1 mg Nabilon (THC))**

Name of marketed product & CBD /THC content (if known):

**Dronabinol for pharmacy-prepared medicinal products (permitted but not approved)**

**Q9** Are there any ongoing approved clinical trials in your country that are developing THC for medical use?

**Yes**

**Q10** Please indicate product name/ trial number/ study phase of any ongoing trials that are developing products of THC for medical use

Product name

**Dronabinol; Eudra-CT: 2006-000439-85; Phase: 2**

Product name

**Dronabinol; Eudra-CT: 2007-001284-30; Phase: 1**

Product name

**Dronabinol; Eudra-CT: 2007-001284-30; Phase: 1**

Product name

**Dronabinol; Eudra-CT: 2008-006881-27; Phase: 1**

Product name

**Dronabinol; Eudra-CT: 2018-000014-38; Phase: 2**

Product name

**THC/Cannabidiol; Eudra-CT: 2013-000596-33; Phase: 1**

Page 7: Medical use: Access

**Q11** Do individuals require a prescription to obtain medical THC?

**Yes**

WHO ECDD Questionnaire: delta-9-tetrahydrocannabinol (THC)

**Q12** What types of professionals are allowed to prescribe THC?

**Medical doctor / psychiatrist**

---

**Q13** What kinds of settings are approved to legally dispense THC in your country?

**Pharmacies**

---

**Q14** If patients use medical THC on prescription or recommendation of a health professional, will they be reimbursed for the costs of their medication?

Other (please specify):  
Authorised finished medicinal products containing THC are reimbursed for the approved indications. Pharmacy-prepared medicinal products containing THC are reimbursed for patients who are severely ill and who have no other alternative in therapies.

---

**Q15** Are any clinical guidelines used in your country for the prescribing of medical THC?

Yes (please specify):  
The German Medical Association (Bundesärztekammer) has published a compilation of frequently asked questions relating to the medical prescription of Cannabis.

---

**Q16** Is there a regulatory agency in your country that monitors THC for medical use?

Yes (please specify):  
There is a non interventional companion survey from the Federal Institute for Drugs and Medical Devices to receive more data about the medical use and benefit of Cannabis. Furthermore, all medicinal Cannabis products are subject to the pharmacovigilance system.

---

**Q17** How would you describe the trend in the number of users of THC for medical use over the last 3 years?

THC **The number has substantially increased**

---

Page 8: Medical use: National legislation

**Q18** In the past 3 years, has your country changed its national legislation around access to cannabis-related substances for medical use?

THC **Yes, my country has changed its legislation**

---

WHO ECDD Questionnaire: delta-9-tetrahydrocannabinol (THC)

**Q19** If yes, what types of legislative changes has your country made for medical use of THC?

Other (please specify):

THC (Dronabinol, Nabilon) is a prescribable narcotic drug for more than 3 years. However, since 1 year pharmacy-prepared medicinal products containing THC are reimbursed for patients who are severely ill and who have no other alternative in therapies.

**Q20** Is your country currently considering changes to its national legislation around access to cannabis and cannabis-related substances for medical use?

THC **No, my country is not preparing changes in its legislation**

**Q21** In your opinion, how do you feel the changed legislation around access to THC for medical use would impact / has impacted public health in your country?

Increased availability for medical use **There would be/ has been a slightly positive impact on public health**

Decreased availability for medical use **There would be /has been a slightly negative impact on public health**

Please explain your response:: See uploaded file: Summary of a scientific analysis concerning the potential and risks of cannabis (CaPRis)

Page 9: Non-medical use

**Q22** On a national level, is THC legally available for non-medical use in your country? **No**

**Q23** Is THC used for cultural, ceremonial, or religious purposes in your country? **No**

**Q24** Does your country collect prevalence data around the use of THC? **No**

Page 10: Prevalence of non-medical cannabis use

**Q25** Prevalence of use of THC amongst adults ( over 18 years of age) **Respondent skipped this question**

**Q26** Prevalence of use of THC for non-medical use amongst young people ( below 18 years of age) **Respondent skipped this question**

WHO ECDD Questionnaire: delta-9-tetrahydrocannabinol (THC)

**Q27** How would you describe the number of users THC for non-medical use over the last 3 years in your country?

Respondent skipped this question

---

Page 11: Public health impact of use: Primary Care

**Q28** Does your country collect data about presentations to primary care settings due to the use of THC?

No

---

Page 12: Primary Care II

**Q29** Number of primary care presentations relating to THC

Respondent skipped this question

**Q30** Does your country collect data about presentations to emergency care settings due to the use of THC?

No

---

Page 13: Public health: Emergency settings

**Q31** Number of individuals in the past year presenting to emergency settings relating to the use of THC

Respondent skipped this question

**Q32** Please list the adverse effects presented for THC at the emergency room/department

Respondent skipped this question

**Q33** Does your country collect data about presentations to substance misuse treatment settings due to the use of THC?

No

---

Page 14: Public health: Substance misuse treatment

**Q34** Number of individuals in the past year presenting to substance misuse treatment due to THC

Respondent skipped this question

**Q35** Does your country collect data about calls to poison centres due to the use of THC?

No

---

Page 15: Public health impact: Poison control centres

**Q36** Number of calls to poison control centres due to the use of THC

Respondent skipped this question

WHO ECDD Questionnaire: delta-9-tetrahydrocannabinol (THC)

**Q37** Does your country collect data about cases of impaired driving due to the use of THC? **No**

---

Page 16: Public health impact: Impaired driving

**Q38** Number of cases of impaired driving due to THC **Respondent skipped this question**

---

Page 17: Non-Medical Use: National legislation

**Q39** In the past 3 years, has your country changed its national legislation around access to THC for non-medical use?

THC **No, my country has not changed its legislation**

---

**Q40** If yes, what types of legislative changes has your country made for non-medical use of THC? **Respondent skipped this question**

---

**Q41** Is your country currently considering changes to its national legislation around access to THC for non-medical use?

THC **No, my country is not preparing changes in its legislation**

---

**Q42** In your opinion, how do you feel the changed legislation around access to THC for non-medical use would impact / has already impacted public health in your country?

Increased availability for non-medical use **There would be/ has been a significantly negative impact on public health**

Decreased availability for non-medical use **There would be/ has been a significantly positive impact on public health**

Please explain your response:: See uploaded file: Summary of a scientific analysis concerning the potential and risks of cannabis (CaPRis)

---

Page 18: Additional comments / information

**Q43** Comments **Respondent skipped this question**

---

**Q44** File upload

**Kurzbericht\_CAPRis.pdf (190KB)**

---

**Q45** File upload

**FAQ Cannabis\_Bundesärztekammer.pdf (269.5KB)**

---

**Q46** File upload

**Respondent skipped this question**

---